Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

INTRODUCTION: Subcutaneous galcanezumab was an effective, well-tolerated preventive treatment for adults with episodic (EM) or chronic migraine (CM) in 4 phase 3 randomized controlled trials: EVOLVE-1, EVOLVE-2, REGAIN, and CONQUER. Number needed to treat (NNT) and to harm (NNH) are metrics of effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Citrome, Leslie, Sánchez del Rio, Margarita, Dong, Yan, Nichols, Russell M., Tockhorn-Heidenreich, Antje, Foster, Shonda A., Stauffer, Virginia L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342379/
https://www.ncbi.nlm.nih.gov/pubmed/34264500
http://dx.doi.org/10.1007/s12325-021-01848-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342379/
https://www.ncbi.nlm.nih.gov/pubmed/34264500
http://dx.doi.org/10.1007/s12325-021-01848-x

Ejemplares similares